Just 54.2% of patients begin treatment within 62 days of their referral, against a target of 85%.
Trending
- Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial
- Work, Money, & a Normal Life
- AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires
- HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia
- Mastectomy, ET Linked to Lower LRR in Young Populations With Breast Cancer
- Revolution Medicines previews ‘novel class’ of cancer treatments
- Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma
- CD39/PD-L1 Inhibition May Improve pCR Rate in Resectable NSCLC

